AMNEAL PHARMACEUTICALS, INC. Business Acquisition, Pro Forma Revenue
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Business Acquisition, Pro Forma Revenue of $2.09 billion for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-03.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2023-03-03
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2021-12-31 was $537.09M, a 5.29% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2021-09-30 was $528.59M, a 1.78% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2020-12-31 was $510.10M, a 4.20% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2020-09-30 was $519.35M, a 14.80% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for fiscal 2021 was $2.09B, a 3.47% increase from fiscal 2020.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for fiscal 2020 was $2.02B, a 4.69% increase from fiscal 2019.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for fiscal 2019 was $1.93B, a 5.11% increase from fiscal 2018.
- AMNEAL PHARMACEUTICALS, INC. business acquisition, pro forma revenue for fiscal 2018 was $1.84B, a 1.64% increase from fiscal 2017.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $537.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $1.07B derived: sum of 2 quarters · filed 2023-03-03 | $2.09B 10-K · filed 2023-03-03 | |||||
| 2021-09-30 | $528.59M 10-Q · filed 2021-11-08 | $1.56B 10-Q · filed 2021-11-08 | ||||||
| 2020-12-31 | $510.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $1.03B derived: sum of 2 quarters · filed 2023-03-03 | $1.56B derived: sum of 3 quarters · filed 2023-03-03 | $2.02B 10-K · filed 2023-03-03 | $2.02B 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $519.35M 10-Q · filed 2021-11-08 | $519.29M 10-Q · filed 2020-11-06 | $1.05B derived: sum of 2 quarters · filed 2021-11-08 | $1.51B 10-Q · filed 2021-11-08 | $1.51B 10-Q · filed 2020-11-06 | $2.07B derived: sum of 4 quarters · filed 2021-11-08 | ||
| 2020-06-30 | $535.08M 10-Q · filed 2021-08-09 | $464.66M 10-Q · filed 2020-08-06 | $1.03B 10-Q · filed 2021-08-09 | $989.97M 10-Q · filed 2020-08-06 | $1.55B derived: sum of 3 quarters · filed 2021-08-09 | $2.00B derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | $525.30M 10-Q · filed 2021-05-07 | $1.01B derived: sum of 2 quarters · filed 2021-05-07 | $1.47B derived: sum of 3 quarters · filed 2021-05-07 | $1.93B derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2019-12-31 | $489.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $941.95M derived: sum of 2 quarters · filed 2021-03-01 | $1.41B derived: sum of 3 quarters · filed 2021-08-09 | $1.93B 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $452.40M 10-Q · filed 2020-11-06 | $917.16M derived: sum of 2 quarters · filed 2021-08-09 | $1.44B 10-Q · filed 2020-11-06 | $1.93B derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2019-06-30 | $464.75M 10-Q · filed 2021-08-09 | $479.89M 10-Q · filed 2020-08-06 | $994.16M 10-Q · filed 2021-08-09 | $991.10M 10-Q · filed 2020-08-06 | $1.47B derived: sum of 3 quarters · filed 2021-08-09 | $1.95B derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2019-03-31 | $511.20M 10-Q · filed 2020-05-11 | $1.01B derived: sum of 2 quarters · filed 2020-05-11 | $1.49B derived: sum of 3 quarters · filed 2020-05-11 | $1.93B derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | $497.53M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $974.01M derived: sum of 2 quarters · filed 2020-03-02 | $1.42B derived: sum of 3 quarters · filed 2020-03-02 | $1.84B 10-K · filed 2020-03-02 | ||||
| 2018-09-30 | $476.49M 10-Q · filed 2018-11-07 | $924.01M derived: sum of 2 quarters · filed 2019-08-05 | $1.34B 10-Q · filed 2019-11-07 | $1.82B derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $447.52M 10-Q · filed 2019-08-05 | $865.07M 10-Q · filed 2019-08-05 | $1.34B derived: sum of 3 quarters · filed 2020-03-02 | $1.80B derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $417.54M 10-Q · filed 2019-05-09 | $893.82M derived: sum of 2 quarters · filed 2020-03-02 | $1.35B derived: sum of 3 quarters · filed 2020-03-02 | $1.82B derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $476.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $937.40M derived: sum of 2 quarters · filed 2020-03-02 | $1.40B derived: sum of 3 quarters · filed 2020-03-02 | $1.81B 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $461.13M 10-Q · filed 2018-11-07 | $923.08M derived: sum of 2 quarters · filed 2018-11-07 | $1.33B 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $461.95M 10-Q · filed 2018-08-09 | $872.04M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | $1.84B 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |